CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
REVENUES:
License fees	$ 362,249	$ 175,419	$ 712,078	$ 211,887
Royalties from product sales	103,315	126,455	210,914	273,857
Grant income	693,480	672,537	777,293	1,074,771
Sale of research products	57,281	59,253	124,005	127,037
Total revenues	1,216,325	1,033,664	1,824,290	1,687,552
Cost of sales	(180,811)	(83,918)	(363,560)	(105,497)
Total revenues, net	1,035,514	949,746	1,460,730	1,582,055
EXPENSES:
Research and development	(5,530,395)	(4,615,436)	(10,975,825)	(8,773,302)
General and administrative	(3,621,570)	(2,413,641)	(7,005,091)	(4,802,337)
Total expenses	(9,151,965)	(7,029,077)	(17,980,916)	(13,575,639)
Loss from operations	(8,116,451)	(6,079,331)	(16,520,186)	(11,993,584)
OTHER INCOME/(EXPENSES):
Interest income, net	579	3,355	1,522	11,636
Other income/(expense), net	(80,541)	85,260	(109,520)	(240,005)
Gain/(loss) on sale/write off of equipment	800	(3,546)	(710)	(3,546)
Total other income/(expense), net	(79,162)	85,069	(108,708)	(231,915)
NET LOSS	(8,195,613)	(5,994,262)	(16,628,894)	(12,225,499)
Less: Net loss attributable to noncontrolling interest	645,848	537,040	1,346,503	1,796,378
NET LOSS ATTRIBUTABLE TO BIOTIME, INC.	(7,549,765)	(5,457,222)	(15,282,391)	(10,429,121)
Foreign currency translation gain (loss)	28,857	(182,947)	177,294	(58,859)
TOTAL COMPREHENSIVE NET LOSS	$ (7,520,908)	$ (5,640,169)	$ (15,105,097)	$ (10,487,980)
BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share)	$ (0.14)	$ (0.11)	$ (0.29)	$ (0.21)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)	53,791,434	50,548,582	52,490,767	50,435,272